Prometic Receives Fast Track Designation from FDA

The Fast Track designation follows the FDA’s recent approval of Prometic’s Investigational New Drug (IND) application and design of the pivotal Phase 2/3 clinical trial in patients with IPF.

“The treatment options for patients with fibrotic diseases like IPF are limited in scope and effectiveness,” said Pierre Laurin, president and chief executive officer of Prometic. “Fast Track designation will allow us to advance PBI-4050 and seek to potentially gain approval in a more efficient process. PBI-4050 has the potential to provide patients with IPF a more effective treatment option. We look forward to demonstrating PBI-4050’s clinical efficacy and strong safety and tolerability profiles in a longer-term, placebo controlled trial.”

Click here to read the full press release.